A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : vWFAg / von Willebrand factor antigen

[Related PubMed/MEDLINE]
Total Number of Papers: 81
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   vWFAg  (>> Co-occurring Abbreviation)
Long Form:   von Willebrand factor antigen
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 The association of PAI-1 with 24 h blood pressure in young healthy adults is influenced by smoking and alcohol use: The African-PREDICT study. MCP-1, PAI-1, PAI-1act
2020 von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma. HCC
2020 Von Willebrand factor, its cleaving protease (ADAMTS13), and inflammation in young adults: The African-PREDICT study. CRP, IL-6, vWF
2018 Bioavailable IGF-1 is beneficially associated with biomarkers of endothelial function in young healthy adults: The African-PREDICT study. ICAM-1, IGF-1, IGFBP-3, VCAM-1
2018 Coagulation Factor Activities Changes Over 5Days in Thawed Fresh Frozen Plasma Stored at Different Initial Storage Temperatures. APTT, FFP, PT
2017 The predictive value of Von Willebrand factor antigen plasma levels in children with acute lung injury. ALI, MSOF, MV, PICU
2017 VAP score as a novel non-invasive liver fibrosis model in patients with chronic hepatitis C. AAR, APRI, AST, CHC, FCI, FI, FIB-4, FibroQ
2017 Von Willebrand factor and alkaline phosphatase predict re-transplantation-free survival after the first liver transplantation. ALP, AUC, LT, MELD, ROC
2016 Evaluation of Early Atherosclerosis Markers in Patients with Inflammatory Bowel Disease. CIMT, FMD, IBD, NMD
10  2016 von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. FVIII-to-PC, MELD, PC, VB
11  2016 von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. HCV
12  2015 Preseason preparation training and endothelial function in elite professional soccer players. ---
13  2014 CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility. EMP
14  2014 Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus. CVD, Fb, PAI-1-Ag, T1DM
15  2014 The influence of hyperprolactinemia on coagulation parameters in females with prolactinomas. APTT, BMI, PRL, PT, TT
16  2014 Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. HPS, HVPG, MELD
17  2014 [Evaluation of Analytical Performance of HISCL TM, a Chemiluminescent Enzyme Immunoassay and the Use of Thrombomodulin as a Marker for Endothelial Dysfunction]. CRP, CV, FIB, PIC, TAT, TM
18  2013 Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. MPs, SCD
19  2013 Platelet-derived microparticles and platelet function profile in children with congenital heart disease. ACHD, CCHD, CHD, GP, Hct, PMPs
20  2013 [Detection of hemophilia A carrier by FⅧ:C/vWFAg ratio]. ---
21  2012 von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. AUC, CSPH, HVPG, MELD, OR
22  2012 [Markers of endothelial activation in rheumatoid arthritis]. CRP, DE, IL-8, RA, RF, sVCAM-1
23  2012 [The effects of activated protein C on the von Willebrand factor and von Willebrand factor cleaving protease of rat aortic endothelial cell induced by lipopolysaccharide]. APC, ELISA, LPS, RAECs
24  2011 Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters. BMI, Fb, FI, HOMA-IR, IR, PAI-1-Ag
25  2010 Activation of the endogenous coagulation system in patients with atrial flutter: relationship to echocardiographic markers of thromboembolic risk. TAT
26  2010 Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. AECA, anti-CL, anti-U1RNP, CVD, FMD, IMT, IMT, MCTD, NMD, TM
27  2010 Prevalence of von Willebrand disease in dogs from Sao Paulo State, Brazil. VWD
28  2010 von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4. CHC, EVR, PPV, SVR
29  2009 Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. ATIII, FFP, FPS, PC
30  2009 Haemostatic markers in patients with abdominal aortic aneurysm and the impact of aneurysm size. PAI-1, t-PA Ag, TAT
31  2008 Activated coagulation in patients with shock due to ruptured abdominal aortic aneurysm. TAT
32  2007 Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus. s-ICAM, VEGF
33  2007 Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. ADP, CADP, CEPI, CTs
34  2007 Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. ALI
35  2006 Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. AECA, MCTD, PAH, TM, TM
36  2005 Clinical correlations of potential activity markers in systemic sclerosis. bET-1, Dpyr, IL-6, NPIIIP, Pyr, sICAM-1, sIL-2r, SSc, sVCAM-1
37  2005 Does body mass index, smoking, lipoprotein levels, surgically induced menopause, hormone replacement therapy, years since menopause, or age affect hemostasis in postmenopausal women? BMI, HDL-C, HRT, PAI-1, TC, TG
38  2004 Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. CRP, sTF
39  2004 Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. CPAP, OSA, sP-sel, TAT
40  2004 [Endothelial parameters in blood plasma of patients suffering from ischaemic heart disease and undergoing surgery with extracorporeal circulation]. PAI-1-Ag, t-PA Ag
41  2003 Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. HMW, LMW, PAI-1, TF, TFPI, tPA, uPA, VEGF
42  2003 [Pulse-therapy with glucocorticoids and cyclophosphamide in the treatment of thromboangiitis obliterans]. CRP, TA
43  2002 Acute hyperglycemia and hyperinsulinemia enhance vasodilatation in Type 1 diabetes mellitus without increasing capillary permeability and inducing endothelial dysfunction. sICAM-1
44  2002 Retained fibrinolytic response and no coagulation activation after acute physical exercise in middle-aged women with previous myocardial infarction. MI, PAI-1, tPA
45  2002 The APTT response of pregnant plasma to unfractionated heparin. APTT, LAH, UFH
46  2001 Atypical variant of acquired von Willebrand syndrome in Wilms tumor: is hyaluronic acid secreted by nephroblastoma cells the cause? AVWS, RCF, VIIIc, VWD
47  2001 Circulating immune complexes induced by food proteins implicated in precocious myocardial infarction. CIC, ELISA, MI, SDS
48  2001 Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. CRP
49  2001 [Von Willebrand factor in hemodialysed patients with chronic renal failure]. ELISA
50  2000 Comparison of fresh frozen plasma with a standardized serum protein solution following therapeutic plasma exchange in patients with autoimmune disease: a prospective controlled clinical trial. ADR, CRP, FFP, FVIIIC, PF4, PTT
51  2000 Correlation between cholesterol, soluble P-selectin, and D-dimer in obese children and adolescents. VIII C
52  2000 Determinants of haemostatic risk factors for coronary heart disease in obese children and adolescents. BMI, CHD, PAI-1-Ag, tPA-ag
53  2000 Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. tPA
54  2000 Evaluation of the von Willebrand factor antigen (vWF-Ag) assay using an immuno-turbidimetric method (STA Liatest vWF) automated on the MDA 180 coagulometer. ELISA
55  2000 Inverse correlation between thyroid function and hemostatic markers for coronary heart disease in obese children and adolescents. CHD, PAI-1-Ag, tPA-ag, VIIc, VIII C
56  2000 Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients. CAV, CHF
57  1998 Effects of histamine and nitric oxide synthase inhibition on plasma levels of von Willebrand factor antigen. CI, L-NMMA, NO, vWF
58  1998 Plasma coagulation profiles in patients with severe primary pulmonary hypertension. PAI, PPH, TAT, tPA
59  1997 Antiendothelial cell antibodies: useful markers of systemic sclerosis. ACE, AECA, ELISA, PRP, SS, TM
60  1997 In vitro platelet function in controlled ovarian hyperstimulation cycles. AA, ADP, ATP, COH, Col
61  1997 Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. PAI-1 activity, PAI-1-Ag, t-PA Ag, vWF activity, WHR
62  1995 Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. FVIII
63  1995 The effects of cardiopulmonary bypass on systemic and coronary levels of von Willebrand factor. CPB
64  1995 Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. ARDS, BALF, TFPI
65  1994 Factor VIII, ABO blood group and the incidence of ischaemic heart disease. IHD, NPHS
66  1994 von Willebrand factor antigen compared with other factors in vasculitic syndromes. RiCof
67  1993 An investigation into the acute vascular effects of riveting. ACE, ET-1
68  1993 Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals. RiCof, tPA
69  1992 An enzyme-linked immunosorbent assay (ELISA) for von Willebrand factor antigen (vWf-Ag) in canine plasma. CV, EID, ELISA
70  1992 von Willebrand factor antigen: a radial immunodiffusion method evaluated and compared with an ELISA method. ---
71  1991 Haemostatic activation and proteinuria as factors in the progression of chronic renal failure. CRF, CRP
72  1991 The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. c-ANCA, FN, PAN, WG
73  1991 Which tests are most useful in distinguishing between reactive thrombocytosis and the thrombocytosis of myeloproliferative disease? MPD, RT
74  1990 Serological and immunohistochemical determination of von Willebrand factor antigen in serum and biopsy specimens from patients with arteritis temporalis and polymyalgia rheumatica. AT, PMR
75  1989 von Willebrand factor is an acute phase reactant in man. CRP
76  1988 Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer. BTG, DIC, FPA, FSP, PC, PF4, VIII C
77  1987 Enhanced release of von Willebrand factor by human endothelial cells in culture in the presence of phorbol myristate acetate and interleukin 1. EC, IL-1, IL-2, PMA
78  1987 Plasma levels of fibronectin in polymyalgia rheumatica giant cell arteritis. ESR, FN, FNG, PMR-GCA
79  1986 Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease. vWd
80  1986 The relationship between von Willebrand factor antigen and fibronectin in human plasma, endothelial cells and fibroblasts in culture. FN
81  1986 Vasopressin and catecholamine secretion during apomorphine-induced nausea mediate acute changes in haemostatic function in man. APTT, ECLT, FPA, FVIIIC